Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1008
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 865–876 of 1,008 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional Results available

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986
Site status not listed — check the official record
View directory record Official record
Conditions
Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
Interventions
Olaparib 300mg tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
81
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV

NCT06013579
Status at this site: Recruiting
View directory record Official record
Conditions
HIV Infections, Cognitive Impairment
Interventions
Phase 1 Gym Exercise HIIT, Phase 1 Gym Exercise CME, Phase 2 Home Exercise Coaching Text Messages, Phase 2 Home Exercise Control Text Messages
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Active, not recruiting Phase 2 Interventional

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Background PAH Therapy
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Aurora, Colorado • Kansas City, Kansas • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional Capacity

NCT05566483
Status at this site: Recruiting
View directory record Official record
Conditions
Post-acute Sequelae of SARS-CoV-2 Infection
Interventions
Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Active, not recruiting Phase 1 Interventional

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236
Site status not listed — check the official record
View directory record Official record
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions
SC291
Biological
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Active, not recruiting Not applicable Interventional

M6-C Artificial Cervical Disc Two-Level IDE Pivotal Study

NCT04982835
Site status not listed — check the official record
View directory record Official record
Conditions
Cervical Disc Degenerative Disorder
Interventions
M6-C Artificial Cervical Disc, ACDF
Device
Lead sponsor
Orthofix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dietary Reversal of the Reprometabolic Syndrome

NCT07227766
Site status not listed — check the official record
View directory record Official record
Conditions
Obesity & Overweight, Infertility, Female
Interventions
Low-fat diet
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Active, not recruiting Phase 4 Interventional

Impact of Vericiguat on Hemodynamics of Heart Failure

NCT05704478
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Failure
Interventions
Vericiguat
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Active, not recruiting Phase 2 Interventional

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

NCT04551430
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Soft-tissue Sarcoma
Interventions
Cabozantinib, Nivolumab, Ipilimumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Stanford, California • Aurora, Colorado • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Recruiting No phase listed Observational

A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

NCT03617939
Status at this site: Recruiting
View directory record Official record
Conditions
Cancer Risk
Interventions
Biospeciman Collection, Survey Assessments, Medical Chart Reviews
Procedure · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2037
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Active, not recruiting Not applicable Interventional

Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection

NCT03033043
Site status not listed — check the official record
View directory record Official record
Conditions
Aortic Dissection Type B
Interventions
Relay Pro Stent-Graft
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
21
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Nov 5, 2026, 2:42 AM EST
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions
VLS-1488
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 5, 2026, 2:42 AM EST

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.